GlassScriptPhysician profile
John Tyler Klein
NPI 1710469705
$1,771.12
in general payments reported to CMS, 2019-2025
18 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $159 · 2021: $283 · 2022: $188 · 2023: $248 · 2024: $243 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.49 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $538.83 | 2021-2025 | Precision 1, Dailies, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $288.53 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $254.30 | 2023-2025 | Miebo, Infuse, Xiidra |
| Regeneron Healthcare Solutions, INC. | $117.83 | 2022-2025 | Eylea Hd |
| Tarsus Pharmaceuticals, INC. | $97.33 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $78.67 | 2020 | |
| Harrow Eye, LLC | $56.46 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $52.81 | 2019-2020 | |
| Dompe US, INC. | $50.74 | 2025 | Oxervate |
| Abbvie INC. | $48.62 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $35.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.17 | 2020-2022 | |
| Rxsight INC | $25.59 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $23.79 | 2025 | Idosetr, Istent Infinite |
| Amgen INC. | $21.22 | 2025 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $18.19 | 2025 | Iyuzeh |
| Coopervision INC. | $15.48 | 2019 | |
| Oyster Point Pharma, INC. | $14.22 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.